Health Interventions to Improve the Medication Efficacy in Tuberculosis Treatment by Jean Leandro dos Santos et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
25 
Health Interventions to Improve  
the Medication Efficacy in  
Tuberculosis Treatment 
Jean Leandro dos Santos, Chung Man Chin, Ednir de Oliveira Vizioli, 
Fernando Rogério Pavan and Luiz Antonio Dutra 
Universidade Estadual Paulista “Júlio de Mesquita Filho” 
Faculdade de Ciências Farmacêuticas – UNESP Araraquara 
Brazil 
1. Introduction  
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. According 
to the World Health Organization (WHO), there are an estimated of 8.8 million new cases 
annually -including 200.000 HIV-infected individuals- and 1.6 million deaths (WHO, 2008). 
Despite some reports demonstrates reduction of new cases, it is extensive in literature data 
showing the problem of drug-resistance and the consequence of this one to the effective 
treatment (FAUCI, 2008). The drug resistance can be caused by several factors such as: 1) 
antibiotic selective pressure characterized by inadequate selection or dosage; 2) immune 
status of the individuals; 3) No compliance by patients; 4) natural selection or any pre-
existing resistances in the infecting clone, among others (Figure 1). 
Nowadays, HIV co-morbidity treatment is a challenge. It has been reported that HIV is a 
potent risk factor to TB disease development. Some studies showed that HIV/TB co-
infection increase 100 times the risk to develop TB disease when compared to people 
infected only with TB (HAVLIR & BARNES, 1999; PITCHENIK et al., 1988). In addition, the 
probability to develop drug resistance is higher in patients under HIV infection treatment 
due mainly drug related problems (Frieden et al. 1993; Gordin et al., 1996). 
One of the first randomized studies about antitubercular drug was performed with 
streptomycin. This drug reduces 50% the mortality of infected patients after 6 months of 
treatment. However, it was observed high rate of resistance in cases of monotherapy. The 
combination of drugs reduces the resistance to TB drugs, therefore the current treatment of 
tuberculosis involves multidrug therapy (Herzog, 1998). 
WHO recommends the use of rifampicin (or rifabutin), isoniazid, pyrazinamide and 
ethambutol by two months followed by rifampicin and isoniazid for four months. The first 
phase of the treatment aims eliminates the bacilli in mutiplicate and semi dormant stage. 
The second stage called the maintenance phase aims eliminate dormant bacilli reducing the 
number of failures and relapses (Bisaglia, 2003). The scheme of treatment is prolonged (6 
months) contributing to no-therapy compliance by some patients. 
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Fig. 1. Some causes of TB drug resistance.  
The lack of therapy adherence is a serious problem to eliminate TB mainly in developing 
countries. Several aspects are related to this problem such as: adverse effects of TB drugs, 
long-term therapy, damage to certain organs (i.e. liver), lack of available drugs and co-
morbidities.  
Another important aspect to be considered in tuberculosis treatment is the unavailability of 
new drugs. The last discovery drug to TB was rifampicin in the 60’s. Despite TB drug 
development efforts have emerged in the last years few advances were reached. Currently, 
there are some drugs, obtained by molecular modification, being evaluated in clinical trials. 
An ideal drug against TB must possess some characteristics that include: broad spectrum of 
action with possibility to be use in resistant strains; adequate pharmacokinetic profile 
increasing the concentration in some tissues target and reduce drug-drug interaction; 
adequate and shorten treatment duration reducing pill burden in order to reduce numbers 
of pills taken increasing the patients compliance (Koul et al, 2011).  
The combination of all these factors discussed above makes difficult TB treatment. Not only 
strategies to discovery new drugs, but rational approach to improve the use of old drugs are 
essential to improve the efficacy of the treatment. This chapter aiming discusses some 
factors to improve medication efficacy in tuberculosis treatment. Some aspects of TB such as 
disease development, resistance and treatment will be discussed. Furthermore therapeutical 
aspects such as drug-drug interaction, patient compliance and some health interventions 
will be present.  
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TB Treatment 
According to WHO new patients is recommended the treatment to receive a daily intensive 
phase of the two months of the isoniazid (H), rifampicin (R), pyrazinamid (P) and 
ethambutol (E); followed by 4 months for the maintenance phase of the H and R 
[2HRZE/4HR] (WHO, 2009). This treatment is highly efficient for the drug-susceptible TB 
patients, but, the questions is what about the latent and MDR (multi-drug resistant) or XDR 
(extremely drug-resistant) TB treatment?  
Latent tuberculosis is individuals infected with M. tuberculosis but has no active disease. 
Although this state not is completely clear, there are two main hypothesis to explain this 
condition: 1) M. tuberculosis persists in a lazy state within granulomatous lesions, but 
periodically recrudesces; 2) the bacterium persisting in a dormant state resides within 
alveolar epithelial cells in the lung apices and adipocytes (Ma et al., 2010). Epidemiologically 
latent infection is responsible to contaminated 1/3 of the world population, and there is no 
specific treatment for it (Koul et al., 2011). However H has been used as preventive therapy 
(IPT) has long been known to markedly reduce the risk of reactivation of latent M. 
tuberculosis infection, but this affirmation not is completely proved and clear (Golub et al., 
2008).  
MDR-TB occurs when the TB mycobacteria are resistant to at least H, R and XDR-TB occur 
when the mycobacteria has the same resistant characteristic than MDR-TB plus resistant to 
any fluoroquinolone, and at least one of three injectable second-line drugs (capreomycin, 
kanamycin, and amikacin). The resistant bacteria are selected due to mainly to failure of the 
treatment. Failures attributed mainly to the desistance of treatment by the patient. To 
understand how the bacteria become resistant is not completely understood, but various 
biochemical pathways to escape the lethal action of drugs can be assigned: (i) decreased 
intracellular accumulation of the antibiotic by an alteration of outer membrane permeability, 
diminished transport across the inner membrane, (ii) alteration of the target by mutation or 
enzymatic modification; (iii) enzymatic detoxification of the drug; and (iv) bypass of the 
drug target. The coexistence of several of these mechanisms in the same host can lead to 
MDR and XDR-TB. (Piddock et al., 2006; De Rossi et al., 2006). Another important question 
that needs to be highlighted is the association of these biochemical resistant pathways with 
the efflux pump system. Efflux is a ubiquitous mechanism responsible for intrinsic and 
acquired drug resistance in prokaryotic and eukaryotic cells. M. tuberculosis presents one of 
the largest numbers of putative drug efflux pumps compared with its genome size. 
Antimicrobial resistance in an efflux mutant is due to one of two mechanisms: (i) expression 
of the efflux pump protein is increased or (ii) the protein contains an amino acid 
substitution(s) that makes the protein more efficient at export (Piddock, 2006).  
MDR treatment, anti-TB drugs are grouped according to efficacy, experience of use and 
drug class. There are five groups and only the group 1 can receive the first line drugs, all 
others groups will receive the second-line drugs namely: kanamycin (Km), amikacin (Am), 
capreomycin (Cm), streptomycin (S), Levofloxacin (Lfx), Moxifloxacin (Mfx), Ofloxacin 
(Ofx), para-aminosalicylic acid (PAS), cycloserine (Cs), terizidone (Trd), ethionamide (Eto), 
protionamide (Pto), clofazimine (Cfz), linezolid (Lzd), amoxicillin/clavulanate (Amx/Clv), 
thioacetazone (Thz), imipenem/cilastatin (Ipm/Cln), clarithromycin (Clr) (WHO, 2009). 
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2. TB therapy problems 
TB treatment presents several challenges to be overcome. The treatment abandonment is one 
of them which contribute to development of resistance by mycobacterium to available 
drugs. The abandonment or lack of adherence occurs when the patient does not attend to 
receive medication for a month or more (Pablós-Méndez et al., 1997). Several factors 
contribute to this situation such as socio-economic factors, adverse effects of drugs, co-
morbidities, environmental factors (familiar, social behavior). In developing countries the 
access to adequate health system is one of the most problems to TB therapy. It is very 
common situation that the population has not medical service neither education level to 
comprehend the therapy. There is a relation between poverty and predisposition to disease 
difficult the TB control. Malnutrition, increased expensive to take medicines and 
stigmatization are some intrinsic factors related to the inadequate control of TB in poor 
countries (Cegielski & McMurray, 2004; Atre et al., 2009; Dhingra et al., 2010; WHO, 2005; 
Hargreaves et al., 2011). Educational levels and employment are conditions related to 
abandonment of therapy. It has been reported that a worker, provider of family without 
adequate financial support present high abandonment rate (64%). An interesting relation is 
also observed when someone analyses the educational level of the patients. Those which 
possess higher education (university) demonstrate high level of adherence despite those 
with low educational level. Low level of knowledge is directed relate to inadequate 
treatment (Grace & Chenhall, 2006). The Table 1 shows the main reasons related to 
treatment abandonment.  
The adverse effect of antitubercular drugs is one the main causes of therapy abandonment. 
Some adverse effects of antitubercular drugs are described above:  
 
 
 
Socio-economic Worker, a provider of family, lack of financial sources for feeding 
and locomotion: 64% abandonment. 
Unemployed: 36% abandonment (finantial problems and low self 
steem) 
Education: illiteracy (20% abandonment), less than 8 years of 
study (72 % abandonment), between 8 and 12 years of study (8% 
abandonment) and more than 13 years (0% abandonment). 
 
Therapeutical Adverse effects relate to antitubercular drugs: nausea, vomiting, 
hyperthermia and edema. 
Denial and oblivion. 
Regimens: 
- 2 months: R/I/P + 4 months R/I = 88% abandonment; 
- 6 months: S/P/E/Et = 8% abandonment; 
- 6 months S/I/Et = 4% abandonment. 
R – rifampicin; I – isoniazid; P- pyrazinamide; S- streptomycin;  
E – ethambutol; Et – ethionamide.  
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Disease related 
problems 
Non-acceptance of diagnosis, riot with the illness. No knowledge 
of the existence of extra-pulmonary forms. No symptoms after 
initial treatment interpreted by patients as a cure (Uplekar et al 
2001). 
 
Health related problems Fractures, improvement of symptoms, mental Illness; 
Hepatitis (do not show tolerance to treatment); 
Patients with co-morbidity 
 
Diabetes / TB = TB infections have more severe, with treatment 
failure rate of 8.5 x higher, which generates most abandoned, 
because this patient needs a longer treatment (Gupta et al, 2011). 
HIV / TB: The patient focuses on the treatment of HIV, at least 
tolerate the associated treatment. It is discouraged when after 
diagnosis of HIV, or vice versa (53% abandonment). 
 
Familiar Death and other diseases in the family, motivation, 
recommendation to stop (by others); 
Living away from family; 
Overpopulation in a single family home (sleeping more than two 
in same bed); 
Absence of familiar support. 
Social behavior and sex An anthropological phenomenon is observed with male younger, 
unmarried and/or separated which seek to preserve their 
particular way of life believing that they are not susceptible to TB 
disease. This group has not a tendency to modify some habits to 
contribute for the TB treatment during the 6 months of treatment 
(Gonçalves et al., 1999).  
 
Risk groups A community in contact with contagious TB or focus intra-
household is recommended prophylaxis with isoniazid, however, 
is not accepted by individuals. Typically, these individuals end up 
contaminating and seek treatment lately; 
Alcoholic: 24% abandonment; 
Smokers: 40% (Mendes & Fensterseifer, 2004) 48.8% (Christmas 
1997) abandoned; 
Drinker and smoker: 86.6% abandonment (Lima et al., 2001); 
Drug addict: 12% abandonment; 
 
Others Patient does not trust in the treatment, doctors or the health 
system itself. 
Wait for the health service; 
Distance from health service;  
System health bureaucracy. 
 
Table 1. Main reasons related to treatment abandonment.  
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 Isoniazid: Peripheral neuritis (prevent with the use of pyridoxine); may occur again, optic 
neuritis, ataxia, mental disturbances and incoordination. Hypersensitivity to isoniazid can 
cause fever, various skin rashes, hepatitis and skin rashes, hematologic reactions may 
occur (agranulocytosis, eosinophilia, thrombocytopenia, anemia); neuritis and optic 
atrophy. Twitches, dizziness, ataxia, paresthesias, numbness, toxic encephalopathy are 
other manifestations of neurotoxicity of isoniazid. It may also appear several mental 
abnormalities. May precipitate seizures in patients with previous history of seizures.  
 Rifampicin: Facial flushing, generalized itching and skin rash, purpura, epistaxis, 
menorrhagia, gingival bleeding and hemolytic anemia. Pseudogripal syndrome with 
fever, malaise, headache, chills and myalgia, which may progress to interstitial 
nephritis, acute tubular necrosis, thrombocytopenia and shock. In the digestive tract: 
Malaise, loss of appetite, nausea, vomiting, jaundice, liver failure and diarrhea.  
 Pirazinamide: Liver damage with elevation of plasmatic AST and ALT is the main 
adverse effect. Furthermore it is observed arthralgia, anorexia, nausea and vomiting, 
dysuria, malaise and fever.  
 Ethambutol: The observed adverse reactions include itching, joint pain, gastrointestinal 
disorders, abdominal pain, malaise, headache, dizziness, mental confusion, 
disorientation and possible hallucinations, acute gout or hyperuricemia. Although rare 
the peripheral neuritis and retrobulbar optic neuritis (blurred vision, eye pain, red-gray 
images, decreased vision) are reported. The retrobulbar optic neuritis is dose-
dependent, occurring more frequently with daily doses of 25 mg / kg and after two 
months of therapy, in many cases is reversible after several weeks or several months.  
In general, the adverse effects related to first line antitubercular drugs include skin rash, 
itch, nausea and vomiting, thrombocytopenia, symptoms influenza-símile, arthralgias and 
neuropsychiatric manifestations (Yee et al., 2003; Fekih et al., 2011; Fountain et al., 2005).  
It has been reported that the rate of adverse effects during the treatment could reach 30% of 
the patients or 7,3 per 100 patients/month. Therapy with four drugs increase the incidence 
to 23,3 events by 100-patients/month. In addition, the adverse effects are used to appear 
during the first 100 days of treatment and the most common effects observed were hepatitis 
(28%), gastrointestinal disorders (19%), skin rash (15%), weakness or tiredness (7%) and joint 
pain (6%) (Yee et al., 2003). 
The hepatotoxicity is a deleterious adverse effect responsible to determine changes in 
therapy. TB first line drugs such as rifampicin, rifabutin, isoniazid and pyrazinamide can 
cause hepatotoxicity, alone isoniazid is responsible to 20% of reported cases. The 
combination of drugs increases the probability to develop hepatotoxicity. Risk factors such 
as HIV co-infection, hepatitis B and/or C, alcohol abuse or the use of some medicines (i.e. 
anticonvulsant) should be taken in consideration due the due to the increased likelihood of 
causing liver toxicity.  
In situation which patients present previous diagnosis of advance liver disease, when the 
doctor wants to keep only one hepatotoxic drug, rifampicin is usually selected. However, 
other agents should be added the therapy such as fluorquinolone, cycloserine and 
aminoglycoside. The treatment time of these schemes can vary from 12-18 months 
(American Thoracic Society, 2003). 
It is important to note that the assessment of adverse effects should be performed 
throughout therapy, and compared with pre-treatment parameters. The patient should be 
prepared to identify adverse effects related to the use of anti-TB drugs. 
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Environment factors are determinants for TB treatment. The family has a crucial role to the 
treatment. The knowledge of the disease by all familiar members is an important factor to 
control TB. After the first phase of the treatment, when some symptoms decrease, is 
common identify problems with adherence by patients. So, educational interventions by 
health professionals are important to improve the TB treatment management. Some studies 
demonstrated that previous cases in the family increase the knowledge and the adherence 
by patients (Costa et al., 2011). However, some factors such live away from family, absence 
of familiar support and overpopulation in a single family home (with more than two people 
sleeping in the same bed) is a risk factor to abandon TB treatment. 
Gender is another factor relate to TB. Worldwide, more men than women are diagnosed 
with TB. This higher TB notification in men is relate to epidemiological differences such as 
risk of exposure, infection and progression to disease. However, it has been reported that 
women have higher case of fatalities in the early reproductive ages and higher rates of 
progression from infection to disease (Holmes et al., 1998).  
The association of TB with co-morbidities is a complicated factors related to increase of 
adverse effects and high rate of abandonment treatment by patients. It has been reported 
that treatment fail is increased 8.5 times in diabetic patients with TB, general relate to 
abandonment. In diabetic group infection with TB seems to be more severe that in people 
no-diabetic (Gupta et al., 2011). 
 
Fig. 2. Some TB therapy problems. 
The abandonment of HIV co-infection patients could reach 53% (Table 1). The 
recommended TB treatment of HIV-negative people is the same of HIV-positive people but 
sometimes the therapy is extended to 9 months or more in patients with extra-pulmonar TB. 
However, some management of the therapy is complicated due to paradoxical reaction, 
drug interactions and the difficulty to ingest a large number of tablets (Yew, 2002). The 
paradoxical reactions, is an exacerbation of TB symptoms, due to due to immune recovery, 
called immune reconstitution syndrome. Although the mechanism is not totally clear it is 
presumed to represent an interaction between the host responses and effects produced by 
mycobacterial products leading to inflammatory lesions (Orlovic & Smego, 2001). Some 
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
534 
symptoms include restart or worsening of fever, lymphadenopathy, dyspnea, worsening of 
brain injury (Navas et al., 2002).  
3. Anti-TB drug interactions 
Concurrent treatment of TB and HIV is associated with a higher risk of adverse reactions 
compared to treatment of either infection alone. The first-line anti-TB drugs isoniazid, 
rifampin, and pyrazinamide may each cause hepatotoxicity, which may be compounded by 
concomitant use of protease inhibitors (PI) and nonnucleoside reverse transcriptase 
inhibitors (NRTI). Pharmacokinetic interactions between HIV and TB regimens can have a 
significant impact on the therapeutic efficacy of each regimen. 
Rifamycin antibiotics, the main drug in TB therapy induce the synthesis of drug 
metabolizing enzymes (cytochrome P450 emzyme system, particulary the CYP 3A4, CYP 
2C8/9 isoenzymes and to a lesser extent CYP2C19 and CYPD6 isozymes; the rifamycins 
vary in their potential as CYP450 inducers. Potency of induction: Rifampin > rifapentine > 
rifabutin. Rifampin also upregulates the synthesis of cytosolic drug-metabolizing enzymes, 
including glucuronosyl transferase, an enzyme involved in the metabolism of zidovudine 
and raltegravir. Potent induction of the cytochrome p450 system by rifampin can lead to 
subtherapeutic levels of the protease inhibitors accompanied by virological failure  
Antiretroviral treatment (ART) improves survival in co-infected TB patients and vice-versa, 
however, these concomitant drug therapy in the early stage can increase risk of paradoxal 
TB- immune reconstitution inflammatory syndrome, risk of overlapping drug toxicities with 
possibility in drug treatment interruption, high pill burden that can impact in adherence 
and increased potential drug-drug interactions. The delayed treatment can promote the 
advancing immunosuppression and the development of others opportunist conditions that 
may increase mortality. 
The estimated cumulative probability to develop an adverse event was significantly higher 
in HIV/TB co-infected in Ruanda patients: 20.9% within the first month of antituberculous 
treatment (vs. 3.0% in HIV-uninfected) and up to 29.9% at two months of treatment (vs. 6.9% 
in HIV-uninfected) (Gordin et al., 1996) 
Rifamycin is related to interact with four classes of anti-HIV drugs (protease inhibitors, non-
nucleoside reverse-transcriptase inhibitors [NNRTI], CCR5-receptor antagonistis and 
integrase inhibitors. Zidovudine, the nucleoside analogues and enfuvirtide do not have 
significant interactions with rifamycins.  
The initial ATR regimens in areas with high rates of TB use efavirenz (in combination 
with nucleoside analogues), because of its potency and durability on randomized clinical 
trials.  
The co-adminstration rifampin decrease plasma concentration of efavirenz but not in a 
significant way. Some expertise suggested an increase of efavirenz to 800 mg in TB/HIV 
concomitant treatment to patients weighing more than 60 kg (WHO guidelines). However, 
Cohen and Meinttjes (2010), do not recommend these proceedings based on the fact that the 
CYP 450 2B6 516 G>T polymorphism, which impairs the function of the primary pathway of 
efavirenz metabolism (2B6) is present in African populations. So, the consequence of even  
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  Cmax AUC Cmin  
nevirapine + 
RIFAMPIN 
Decrease plasma 
Concentration 
Caution: 
Sub-therapeutic 
dosage found 
↓50% ↓58% ↓68% The standard dose of 
neveriapine should be used 
among patients taking 
rifampin (200 mg daily for 2 
weeks, followed by 200 mg 
twice daily 
 
*Increasing nevirapine dose 
by 50% to 300 mg twice/daily 
would achieve therapeutic 
concentration but safety has 
not been adequately explored 
as a routine clinical practice 
and my result in 
hypersensivity reactions.  
 
nevirapine + 
RIFABUTIN 
Not significant 
changes in plasma 
concentration 
 
   300 mg rifabutin daily or 
thrice weekly 
no changes recommended 
Efavirenz + 
RIFAMPIN 
not significant  
decrease plasma 
concentration 
 
↓24% ↓25% ↓22% Rifampin 600 mg once/day  
200 mg efanvirenz twice/day  
No changes recommended 
 
 Increase clinical 
toxicity : anxiety, 
depression, 
hepatitis (mainly 
in African 
descendent) 
* efavirenz has 
been associated 
with 
hepatotoxicity 
during 
postmarketing use. 
-co-administration 
of drugs with 
caution: drugs that 
induces liver 
damages such as 
acetaminophen, 
kava-kava, statins, 
metformin 
 
   (600 mg once daily) in 
combination with an anti-TB 
regimen containing rifampin 
(480 to 720 mg/day based on 
body weight) for 7 days 
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Efavirenz + 
RIFABUTIN 
↓rifabutin plasma 
concentration 
 ↓ 38%  Recommendation: ↑ to 450-
600 mg of rifabutin (daily or 
intermittent) 
 
Delavirdine 
+ 
RIFAMPIN 
Strongly ↓ 
delavirdine plasma 
concentration  
NOT 
RECOMMEND 
CONCOMITANT 
USE 
↓90%, ↓97% ↓100% rifampin (600 mg once daily 
for 15 days) ↓ plasma 
concentration of delavirdine 
(400 mg 3x/ day for 30 days) 
Delavirdine 
+ 
RIFABUTIN 
Strongly ↓ 
delavirdine plasma 
concentration and 
↑rifabutin 
concentration by 
100% (AUC) 
NOT 
RECOMMEND 
CONCOMITANT 
USE 
 
↓72% ↓82% ↓94% 300 mg once daily for 15 days  
Etravirine + 
RIFAMPIN 
Strongly ↓ 
etravirine plasma 
concentration  
NOT 
RECOMMEND 
CONCOMITANT 
USE 
 
   Predicted (etravirine is a 
substrate of CYP450 2C19, 
2C9, and 3A4).  
 The risk of 
peripheral 
neuropathy may 
be increased 
during concurrent 
use of two or more 
agents that are 
associated with 
this adverse effect. 
In some cases, the 
neuropathy may 
progress or 
become 
irreversible despite 
discontinuation of 
the medications 
 
   + ETHABUTOL  
+ ISONIAZIDE 
(same effect can be observed 
when use ethambutol + 
isoniazide only) 
 
www.intechopen.com
 
Health Interventions to Improve the Medication Efficacy in Tuberculosis Treatment 
 
537 
Etravirine + 
RIFAMPIN 
+ food  ↓50%  Food increase bioavailabitily 
of etravirine (unknown 
mechanism, but ranging from 
345 kilocalories containing 17 
grams fat to 1160 kilocalories 
containing 70 grams fat did 
not impact on etravirine 
bioavailability 
Etravirine + 
RIFABUTIN 
Decrease etravirine 
Cmin  
 
  ↓ 45% No clinical experience. 
(300 mg rifabutin daily or 3 x 
weekly) 
No changes recommended 
      
Atazanavir * 
+ 
RIFAMPIN 
Strongly ↓ 
atazanavir plasma 
concentration 
NOT 
RECOMMEND 
CONCOMITANT 
USE 
 ↓95%  * with etravirine may ↓ 
atazanavir, with or without 
low-dose ritonavir as a 
pharmacokinetic booster. The 
mechanism is etravirine 
induction of CYP450 3A4, the 
isoenzyme responsible for the 
metabolic clearance of 
atazanavir and other protease 
inhibitors 
 
Atazanavir 
+ 
RIFABUTIN  
Increase rifabutin 
plasma 
concentration 
 ↑250%  Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week 
 + food  
Recommendation: 
To ensure maximal 
oral absorption of 
atazanavir, it 
should be 
administered with 
or immediately 
after a meal 
 
↑57% ↑70%  administration with a light 
meal ↑increased AUC of a 
single 400 mg dose of 
atazanavir relative to the 
fasting state. 
 
Fos-
amprenavir 
+ 
RIFAMPIN 
Strongly decrease 
fosamprenavir 
plasma 
concentration – 
NOT 
RECOMMEND 
CONCOMITANT 
USE 
 
 ↓75-95%  the mechanism is rifampin 
induction of CYP450 3A4, the 
isoenzyme responsible for the 
metabolic clearance of PIs. 
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Fos-
amprenavir 
+ 
RIFABUTIN 
Increase 
significantly 
rifabutin plasma 
and 25-) 
desacetylrifabutin 
in  
7.39 fold(Cmax) 
13.35 fold (AUC) 
32.9 fold (Cmin) 
Use with caution 
↑119% ↑193% ↑271% The mechanism is 
amprenavir inhibition of 
CYP450 3A4, the isoenzyme 
responsible for the metabolic 
clearance of rifabutin and 25-
O-desacetylrifabutin 
Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week 
saquinavir 
/indinavir or 
nelfinavir + 
RIFAMPIN 
Strongly decrease 
of protease 
inhibitors (PIs) 
plasma 
concentration  
 NOT 
RECOMMEND 
CONCOMITANT 
USE 
 ↓75% to 
95% 
 The mechanism is rifampin 
induction of CYP450 3A4, the 
isoenzyme responsible for the 
metabolic clearance of PIs. 
Indinavir + 
RIFABUTIN 
↑ RIFABUTIN 
concentration and 
↓ indinavir by 34% 
 ↑170%  Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week 
nelfinavir + 
RIFABUTIN 
↑ RIFABUTIN 
concentration 
 ↑207%  Not significant change in 
nelfinavir concentration. 
Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week.  
Ritonavir + 
RIFAMPIN 
 
Use with caution 
 ↓35%  no change in rifampin 
concentration (600 mg/day)  
rifampin will decrease the 
level or effect of ritonavir by 
P-glycoprotein (MDR1) efflux 
transporter 
Recommedantion: Monitor 
for antiretroviral activity of 
ritonavir 
 
Ritonavir + 
saquinavir + 
RIFAMPIN  
Hepatotoxicity. 
Transaminase 
elevations up to or 
even exceeding 20 
times the upper 
limit of normal.(38 
%) 
Use with caution  
   Drug-induced hepatitis with 
marked ↑ transaminase has 
been observed in healthy 
volunteers receiving rifampin 
600 mg once daily with 
ritonavir 100 mg and 
saquinavir 1000 mg twice 
daily (i.e., ritonavir-boosted 
saquinavir). The mechanism 
has not been described. 
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Ritonavir + 
lopinavir + 
rifampin  
Hepatotoxicity.  
Use with caution  
   Lopinavir / ritonavir– 2 
tablets (200 mg of lopinavir 
with 50 mg of ritonavir) + 300 
mg of ritonavir twice-daily + 
600 mg rifampin/day 
Have favorable 
pharmacokinetic and clinical 
data among young children 
 
      
Ritonavir + 
lopinavir + 
rifampin 
Rifampin decrease 
plasma 
concentration of 
lopinavir  
Use with caution: 
 
   Increase the dose of lopinavir 
/ ritonavir to 4 tablets (200 
mg of lopinavir with 50 mg of 
ritonavir) twice-daily. This 
combination resulted in 
hepatitis in all adult healthy 
volunteers in an initial study. 
 
      
Ritonavir + 
lopinavir  
Rifabutin 
↑ RIFABUTIN and 
25-o-desacetil 
rifabutin (47,5 
fold) concentration 
  
 303%  Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week 
atazanavir/ 
tipranavir or 
darunavir + 
ritonavir + 
rifampin 
Rifampin strongly 
decrease 
of protease 
inhibitors (PIs) 
plasma 
concentration – 
NOT 
RECOMMEND 
CONCOMITANT 
USE 
 
   The mechanism is rifampin 
induction of CYP450 3A4, the 
isoenzyme responsible for the 
metabolic clearance of PIs. 
Ritonavir + 
saquinavir/i
ndinavir/am
prenavir/fos
-
amprenavir/
atazanavir/ti
pranavir or 
darunavir + 
RIFABUTIN 
 
↑ RIFABUTIN and 
25-o-desacetil 
rifabutin 
concentration 
(varyng degreee) 
   Recommendation: ↓ribatutin 
dose to 150 mg/day or 3 x 
week 
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Maraviroc + 
rifampin 
↓ maraviroc 
plasma 
concentration 
↓66% ↓63% ↓ 78% No clinical experience with 
increased dose of maraviroc + 
rifampin 
Recommendation: no changes 
in rifampin dose (600 
mg/day) 
Maraviroc + 
rifampin 
Patients with 
severe renal 
impairment or 
end-stage renal 
disease (CrCl <30 
mL/min) given 
maraviroc may 
have an increased 
risk of postural 
hypotension due 
to increased 
maraviroc 
exposure. 
Moreover, these 
patients often have 
cardiovascular 
comorbidities that 
could predispose 
them to adverse 
cardiovascular 
events triggered 
by postural 
hypotension.  
   No studies have been 
performed in subjects with 
severe renal impairment or 
ESRD co-treated with 
maraviroc and potent 
CYP450 3A4 inducers. Hence, 
no dosage recommendation 
for maraviroc is available for 
these patients. 
Maraviroc + 
rifabutin 
Not studied     
Raltegravir 
+ rifampin 
↓ Raltegravir 
plasma 
concentration 
 ↓ 40-
61% 
 No clinical experience with 
increased dose of raltegravir 
+ rifampin 
Recommendation: no changes 
in rifampin dose  
(600 mg/day) 
 
Raltegravir 
+ rifabutin 
No studied     
Isoniazid + 
indinavir 
↑  ↑13%  The mechanism probably is 
competitive inhibition of 
isoniazid metabolism 
Recommendation: monitor 
isoniazide-related toxicity 
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Isoniazid + 
lopinavir 
The magnitude 
and clinical 
significance of this 
interaction are 
unknown 
   Coadministration with 
inhibitors of CYP450 3A4 
may increase the plasma 
concentrations of lopinavir, 
which is metabolized by the 
isoenzyme 
Streptomyci
n + 
tenofovir 
Coadministration 
of tenofovir with 
other nephrotoxic 
agents may 
increase the risk 
and severity of 
renal impairment 
due to additive 
effects on the 
kidney. 
Additionally, renal 
impairment 
secondary to the 
use of these agents 
may reduce the 
clearance of 
tenofovir, which is 
primarily 
eliminated by 
renal excretion. 
 
   the risk is low in patients 
with adequate renal function 
receiving the normally 
recommended dosage but 
may increase in patients with 
underlying renal impairment 
Zidovudine 
+ rifampin 
↓ zidovudine 
plasma 
concentration not 
significantly 
rifabutin also 
reportedly 
decreased 
zidovudine AUC 
by 32% and 
increased its 
clearance by 43%  
   rifampin (600 mg orally once 
a day for 14 days) 
recomemmendation Monitor 
for antiretroviral activity of 
zidovudine 
Table 2. Antitubercular Drug Interactions. 
No changes were observed when use nevirapine and rifabutin. Others some important 
considerations area presented below: 
TB/HIV treatment need to avoid co-administration: with potent inducers of CYP450 isoenzymes 
such as carbamazepine, phenobarbital, phenytoin, rifampin and rifapentine due the risk of 
reduced viral susceptibility and resistance development associated with sub-therapeutic 
antiretroviral drug levels.  
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
542 
The use of tenofovir in HIV/TB need avoid the co-administration: with other potentially 
nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin 
antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium 
nitrate; lithium; mesalazine; certain immunosuppressants; intravenous bisphosphonates; 
intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or 
chronic use of nonsteroidal anti-inflammatory agents. Renal function should be evaluated 
prior to and during therapy with tenofovir. Patients with renal insufficiency at baseline or 
during treatment may require dosage adjustment in accordance with the manufacturer's 
product labeling. 
The use of efavirenz in HIV/TB need avoid the co-administration: with potentially hepatotoxicity 
agents: pyrazinamide, isoniazid, acetaminophen; alcohol; androgens and anabolic steroids; 
azole antifungal agents; ACE inhibitors; endothelin receptor antagonists; interferons; other 
nucleoside reverse transcriptase inhibitors; retinoids; thiazolidinediones; anticonvulsants 
such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering 
medications such as fenofibrate, HMG-CoA reductase inhibitors, and niacin; herbals and 
nutritional supplements such as chaparral, comfrey, DHEA, kava, pennyroyal oil, and red 
yeast rice. Patients should be advised to seek medical attention if they experience potential 
signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, 
vomiting, fatigue, right upper quadrant pain, dark urine, light-colored stools, and jaundice. 
Monitoring of liver function should occur before and during treatment, especially in 
patients with other hepatic disease (including hepatitis B or C co-infection) or marked 
transaminase elevations. The benefit of continued therapy with efavirenz should be 
considered against the unknown risks of significant liver toxicity in patients who develop 
persistent elevations of serum transaminases greater than five times the upper limit of 
normal. 
The use of tenofovir in HIV/TB treatment with streptomycin: Caution for renal function 
impairment due to additive effects on the kidney. The deleterious effect on the kindney can 
occur with concomitant use of others nephrotoxic drugs such as aminoglycosides; 
polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; 
foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain 
immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high 
intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-
inflammatory agents. Renal function should be evaluated prior to and during therapy. 
Patients with renal insufficiency at baseline or during treatment may require dosage 
adjustment in accordance with the manufacturer's product labeling. 
The use of maraviroc in HIV/TB treatment with rifampin and others CYP 450 3A4 inhibitors: 
maraviroc should be administered at a dosage of 600 mg twice daily during 
coadministration with potent CYP450 3A4 inducers such as efavirenz, rifampin, 
carbamazepine, phenobarbital, and phenytoin. However, if a potent CYP450 3A4 inhibitor 
such as itraconazole, ketoconazole, delavirdine, clarithromycin, telithromycin, nefazodone, 
or any protease inhibitor (except tipranavir + ritonavir) is also used in combination with the 
inducer, then maraviroc dosage should be reduced to 150 mg twice daily. Maraviroc is 
contraindicated for use in combination with potent CYP450 3A4 inducers in patients with 
severe renal impairment or end-stage renal disease (CrCl <30 mL/min). 
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The use of Isoniazid in HIV/TB treatment with ritonavir/lopinavir and others PIs: The isoniazid 
will increase the level or effect of PIs by affecting hepatic/intestinal enzyme CYP3A4 
metabolism. Avoid co-administration with others inhibitors of the hepatic/intestinal 
enzyme CYP3A4 metabolism such as macrolide antibiotics, itraconazole, ketoconazole, 
nefazodone, fluconazole, verapamil, diltiazen, grapefruit juice. 
Isoniazid + ethambutol: increase the risk of peripheral neuropathy: burning, tingling, pain, or 
numbness in the hands and feet 
Isoniazid + rifampin/rifabutin: The risk of hepatotoxicity is greater when rifampin and 
isoniazid are given concomitantly than when either drug is given alone. Rifampin alters the 
metabolism of isoniazid and increase the amount of toxic metabolites. Similar reaction may 
occur with rifabutin and isoniazid. Patients who are elderly, have hepatic impairment, are 
slow acetylators of isoniazid, drink alcohol daily, are female, or are taking other CYP450-
inducing agents may be at greater risk of hepatotoxicity. Recommend the monitoring for 
clinical or laboratory evidence of hepatic function during the treatment. Discontinuation of 
either or both drugs may be necessary when simptoms of hepatite such as fatigue, 
weakness, malaise, anorexia, nausea, or vomiting appears. 
Isoniazid + food: Food significantly reduces isoniazid absorption, increasing the risk of 
therapeutic failure or resistance. The mechanism is unknown. In addition, the ingestion of 
certain histamine-rich fish (e.g., tuna) and cheeses during isoniazid therapy may cause a 
flushing reaction in some patients. The proposed mechanism is inhibition of monoamine 
oxidase and histaminase by isoniazid, resulting in histamine intoxication. The associated 
symptoms is: flushing, tachycardia, chills, headache, nausea, vomiting, diarrhea, burning 
sensation, sweating, or shortness of breath after eating certain foods. Isoniazid cause 
depletion of B6 vitamin during the treatment. Since HIV-infected persons are at increased 
risk for isoniazid-induced peripheral neuropathy, these patients should take vitamin B6 and 
avoid antiretroviral drugs with potential peripheral neurotoxicity (e.g., stavudine and 
didanosine).  
4. Adherence to therapy – Process to improve medication efficacy 
It has been reported that treatment abandonment rate reaches until 25% of all patients 
during the treatment (Veronesi & Focaccia, 1996). In developing countries such as Brazil, 
this rates decreased in the last years to 4,5%, but it is possible to find out in some regions 
values until 20,3% (Costa, Gonçalves & Menezes, 1998; Lima et al., 2001). The WHO’s 
recommendation is that abandonment rates must be until 5%, however, it is possible to find 
in some countries such as Colombia abandonment rates of 65,6% (Mateus-Solarte & 
Carvajal-Barona, 2008). 
In order to reduce the abandonment of therapy and ensure the correct treatment of patients 
some strategies have been adopted to improve adherence to therapy. According to WHO 
"Adherence corresponds to the behavior of one person - in terms of taking a drug, a diet or 
executing lifestyle changes - that is in accordance with recommendations arising from health 
professionals" (WHO, 2003). 
Adherence to therapy is a serious problem responsible for the evolution of diseases and 
complications, loss of quality of life and even death. In the United States it is estimated that 
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the cost of low compliance reach over $ 147 billion (Council on Patient Information and 
Education, 2007). WHO estimate that rate of adherence of patients which treat chronic 
diseases is only 50% (WHO, 2003). These same values were found in a study with TB 
patients (Cuneo, 1989). 
Literature reports show that interventions to promote adherence are effective in short 
treatments, but these same interventions are less effective in prolonged treatments. In the 
latter situation it requires a combination of strategies, becoming more complex the 
interventions performed by health professionals (Haynes et al., 2009). 
Several methods are available in the literature to assess adherence to treatment. These 
methods can be divided into direct and indirect. In direct methods is possible to quantify the 
drug in the body. These methods are expensive, invasive and not available for all drugs, 
however are suitable methods to say whether or not adherence to therapy allowing include 
adjust the dose. The indirect methods allow assessing the use of medicines by health 
professionals. These methods are usually overestimated and with low sensitivity. Among 
the indirect methods can include: patient’s self-report; prescriber’s report; pill count; 
measurement of prescription replacement (allowing indirect evaluation of non-compliance 
by the lack of access to medication). Strategies using devices of separation and counting of 
medicines may be useful for patients who do not understand the regimen. These devices can 
be purchased at pharmacies and separate properly in accordance with the therapy the 
patient by the pharmacist. 
However, in the therapy of tuberculosis, one of the strategies most used and recommended 
by the World Health Organization (WHO) treatment involves supervised therapy (DOTS - 
Directly Observed Therapy). DOTS strategy includes the delivery of a short course of 
standard drugs, lasting 6 months for new Patients (and 8 months for retreatment Patients). 
The delivery includes the direct observation of therapy (DOT), either by a health worker or 
by caregiver (WHO, 2002). 
During the promotion of strategies to increase adherence is important to consider some 
factors related to therapy adherence that may be related to: patient, health professional, the 
disease condition, treatment and health care system (and the policies government). 
With regard to the patient an important strategy to be adopted is empowerment. This 
strategy is an educational intervention that aims to transfer responsibilities to patients which 
is tone of the most important person responsible to conduct the therapy, based in the 
principle that the decision to follow or not the treatment is only taken by the patient. The 
patient must know about the disease and treatment to participate in the process of using the 
medicine. Factors such as social stigma are common in patients with tuberculosis, however, 
this factor must be worked in the intervention. Economic factors and access to health 
services are factors that also interfere with the patient's decision to adhere to therapy or not. 
With regard to health professionals, active participation is required in treating patients, 
because is often the situation that them cannot understand the proper way to use the anti-
tubercular drugs. The treatment cannot be seen as the sole responsibility of the patient. 
Health professionals have a large portion of the contribution of adherence to treatment. 
With regard to health status, disease severity and the observation of improvement with the 
medicines use is important for maintenance adherence. In situations where the goal of 
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therapy is not immediately improve the main symptoms, should be established an accord 
with the patients which should be aware of the goals of therapy. Treatment should be 
simplified to suit the patient's situation. Complex dosing regimens tend have higher 
dropout rates. The health system has an important role in the adherence. Access to 
professional and medicines is a determining factor for treatment. There is no possibility to 
discuss adherence even if the patients do not have access to health care. In this case, it is 
essential to adopt policies to control diseases such as tuberculosis ensuring access to the 
entire population. 
Several strategies have been described in the literature to promote adherence to therapy. 
Educational interventions may involve pedagogical strategies (oral or written) aiming 
increase the knowledge. This strategy can be used individually or collectively. The uses of 
written or audiovisual materials help the patient to understand the strategy. 
Behavioral interventions aimed changing certain habits. They are guided by theories about 
behavior change. In these strategies the role of health professionals is essential in promoting 
adherence. This one can work with combinations of rewards and communication strategies, 
such as reminders to join the proposed therapy. Praise for the efforts is the reward 
commonly used. The possibility of monitoring the condition at home is also very useful and 
enables patient involvement in the action plan proposed. 
Interventions with affective character take into account social relationships and may be done 
with the patient or the family. Family visits provide a good opportunity for this type of 
intervention. The professional can intervene, in educational way, with all the family doing 
them to understand the situation and help the patient. In TB intervention the combination of 
strategies seems to be more appropriate to increase therapy adherence.  
5. Pharmacotherapeutic monitoring  
Some care should be taken into account in monitoring patients for tuberculosis to detect 
adverse effects or ineffective therapy since the beginning of treatment. After 3 months of 
treatment, most patients (90-95%) will have negative smears (American Thoracic Society, 
2003). Thus, situations of therapeutical inefficacy will be characterized with smear-positive 
after this period. Among factors responsible for ineffective treatment can be mentioned: 
bacterial resistance, poor absorption of drugs, inadequate adherence to treatment and drug 
interactions (Figure 3).  
Some adverse effects such as peripheral neuritis induced by isoniazid can be prevented by 
supplementation with vitamin B6 (pyridoxine). This approach should be considered in 
special situations such as malnutrition, pregnancy, HIV co-infection and alcohol abuse. 
Monitoring liver function is especially important for patients with any risk factor. About 
20% of patients will have elevated levels of liver transaminases without symptoms. In such 
cases, after treatment the enzymes return to levels considered normal. Hepatitis should be 
suspected only when the elevation of transaminases is three to five times higher than 
considered normal associated with symptoms such as nausea, vomiting and abdominal 
pain. Some risk factors for hepatotoxicity are: chronic liver disease or hepatitis, alcohol 
abuse, use of isoniazid, female, HIV infection, low body mass index and age over 60 years 
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Fig. 3. Some factors responsible to inefficacy. 
The action plan for monitoring patients with hepatotoxicity during the treatment includes 
withdrawal of all medicines. After the reduction of transaminases levels, reintroduction of 
individual drug must be re-thinking. It is recommended to start treatment with rifampicin 
(less hepatotoxic), and between 3-7 days to introduce a new drug. Treatment regimens 
without isoniazid are possible. In this last case, one possibility is treating the patient with 
rifampicin, ethambutol and pyrazinamide for six months. 
Drug interactions should be identified and prevented. Beyond the hepatotoxic effect already 
discussed, some antituberculosis drugs like rifampicin are metabolic enzymatic inducers 
and may interfere with the metabolism of many drugs. One example is the oral 
contraceptive whose effectiveness can be compromised with concomitant use of rifampicin. 
In these situations alternative reproductive control methods should be used. Isoniazid may 
increase serum levels of drugs of narrow therapeutic index such as theophylline used by 
asthma patients. 
Regimen that includes rifabutin is generally preferred, as rifabutin appears to be as effective 
as rifampin but is a much less potent inducer of CYP450 3A4. Non rifamycin-containing 
regimens is related to higher rates of treatment relapse and failure; longer treatment 
duration with increased adverse effects and higher mortality rates. This regimen is only 
recommended to patients who are intolerant of rifamycins or are infected with rifamycin-
resistant strains.  
Usual dosages of rifampin may be used in patients receiving ritonavir 600 mg twice/day or 
ritonavir 400 mg twice/day in combination with another PI at reduced dosage (e.g., 
saquinavir 400 mg twice/ day). If the patients have not begun antiretroviral therapy at the 
time TB treatment is initiated, clinicians may also consider using rifampin and postponing 
ATR therapy, because in the early HIV stage of the disease, there is low risk of HIV disease 
progression or death. During this period the physician may monitor CD4 cell count and 
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postpone antiretroviral therapy until TB treatment is complete. However, the optimal time 
for starting ATR therapy should be individualized based on initial response to TB treatment 
and occurrence of adverse effects such as IRIS.  
A patient who cannot take efavirenz, and when rifabutin is not available, the alternative is 
nevirapine - with rifampin. The pharmacokinetic effect of the rifamycin is moderate in this 
regimen. When used with isoniazid, rifampin, and pyrazinamide, there is some concern 
about hepatotoxicity. However, given the risk of reduced viral susceptibility and resistance 
development associated with subtherapeutic antiretroviral drug levels of nevirapine, some 
experts recommend that alternative antimycobacterial agents be considered in patients 
already receiving effective nevirapine-containing antiretroviral therapy. 
Other alternatives for patients who cannot take efavirenz, and when rifabutin is not 
available, are as follows: rifampin with a) zidovudine/lamivudine/abacavir/tenofovir 
treatment; b) zidovudine/lamivudine/tenofovir or c) zidovudine/lamivudine/abacavir. 
The toxicity of these alternative regimens is primarily anemia. Pharmacokinetic concerns 
are a 50% decrease in zidovudine and the effect on abacavir is not yet evaluated. For  
the treatment of latent TB infection, a nine-month regimen of isoniazid may be 
considered.  
In general, treatment of TB /HIV in the context of ATR therapy is complex and requires an 
individualized approach. Experts in the treatment of HIV-related tuberculosis should be 
consulted, and TB and HIV care providers should work in close coordination throughout 
the best treatment considering patient quality of life. 
Additional care should be conducted with patients who have resistant infection. To decrease 
the resistance some principles should be adopted: a) the scheme more effective should be 
adopted, b) the therapeutic regimen should include at least three antimycobacterial drugs,  
c) the treatment should be daily and preferably monitorate by health professional and d) 
medicines should not be left for possible "future use". 
In situations of resistance to isoniazid, one possibility is the use of rifampicin, pyrazinamide, 
ethambutol (and some fluoroquinolone) for a period of 6 months. For resistance to 
rifampicin and isoniazid regimen can be use fluoroquinolone, pyrazinamide and 
ethambutol associated with some other drug for a period of 18-24 months. In situations of 
resistance to rifampin, isoniazid, pyrazinamide (or ethambutol) the scheme would be to use 
a fluoquinolone (ethambutol or pyrazinamide depending on the susceptibility) and two 
alternative agents for a period of 24 months. 
In cases of latent infection, correctly detected, should be assessed the risk and benefit of 
treatment. People living with HIV, immunocompromised, malnourished, drug users and 
from endemic regions with positive test to TB are considered at risk of developing 
tuberculosis. A study by Wilkinson and colleagues (1998) demonstrated that treatment for 
latent infection in HIV people decreased by 43% the risk of developing tuberculosis 
(Wilkinson et al., 1998). Among the schemes that have been proposed that it should be 
noted: a) isoniazid for 6-9 months in the absence of active infection b) rifampicin and 
isoniazid for 3 months and others (Balcells et al. 2006; Ena et al., 2005). 
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All these factors must be taken into account during the pharmacotherapeutic monitoring of 
tuberculosis patients to adequate the therapy and improve quality of life of patients with 
tuberculosis. 
6. Conclusion  
The current TB treatment presents several challenges. The absence of development new 
drugs is the cruelest face of this disease. This fact associated with inadequate treatment 
and TB-drug resistance contributes to survival of the disease today. Anti-TB therapy has 
several problems relate to noncompliance, lack of adherence to therapy, patients with co-
morbidity, socio-economic factors, environmental factors and problems related to drugs 
such as adverse effects and drug interactions. Health interventions can improve the 
medication efficacy, reduce the resistance and improve patients quality of life. 
Pharmacotherapeutic follow-up and adequate strategies to increase therapy adherence are 
important factors to be monitored during TB therapy. It is important to keep in mind that 
interventions that guarantee the adequate use of the medication are the first step to 
improve TB treatment.  
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